Friday, March 10th, 2023.
Huntington Medical Research Institutes, 686 S. Fair Oaks Ave., Pasadena, CA 91105
(Friday, March 10, 2023) of the symposium will include didactic lectures and panel discussions from thought leaders and leading scientists who have actively contributed to the field in the intervening decade. We invite health care providers, researchers, trainees, journal editors, as well as representatives of industry and government concerned with promotion and regulation of PDE-5 inhibitors to register to attend in the Registration Tab.
Timing (Pacific) | Agenda | Speaker |
---|---|---|
8:00 AM - 8:35 AM | Coffee and Continental Breakfast | |
8:35 AM - 8:40 AM | Introduction and Welcome | Julia Bradsher PhD, MBA |
8:40 AM - 8:45 AM | Meeting Overview and Purpose | Robert A. Kloner MD, PhD
Raymond Rosen PhD |
Section on ED: The Workup in 2023 | Moderator: Robert A. Kloner MD, PhD |
|
8:45 AM - 9:00 AM | “Work-up for ED in 2023. Is the Princeton 3 algorithm still correct, and what is the role of telemedicine?” | Martin Miner MD |
9:00 AM - 9:15 AM | “Is ED an independent risk factor or risk marker for cardiovascular disease and what is the role of CT Calcium Scoring?” | Michael Blaha MD, MPH |
9:15 AM - 9:30 AM | “Work- up of young men with ED. Do younger men with ED have greater risk of cardiovascular and all- cause mortality?” | Tobias Kohler MD, MPH |
9:30 AM - 9:45 AM | “Update on psychologic impact of ED and impact of treating ED.” | Raymond Rosen PhD |
9:45 AM - 10:15 AM | PANEL 1 | Moderators: Robert A. Kloner MD, PhD Hossein Sadeghi-Nejad, MD Martin Miner MD Michael Blaha MD, MPH Tobias Kohler MD, MPH Raymond Rosen PhD ... More |
10:15 AM - 10:35 AM | COFFEE BREAK | |
Section on Therapy for ED: Focus on PDE 5 inhibitors | Moderator: Raymond Rosen PhD |
|
10:35 AM - 10:50 AM | “Update on PDE-5 inhibitors. Safety, new PDE-5 inhibitors, over- the-counter PDE-5 inhibitors?” | Kevin McVary MD |
10:50 AM - 11:05 AM | “Nutritional supplements and the safety issues around adding PDE-5 inhibitors to dietary supplements.” | Ira Sharlip MD |
11:05 AM - 11:20 AM | “Recent studies on safety of PDE-5 inhibitors with antihypertensive medicines and nitrates. Should nitrates remain a contraindication or now be considered a warning?” | Peter Ganz MD |
11:20 AM - 11:50 AM | PANEL 2 | Moderators: Raymond Rosen PhD Richard Sadovsky MD Mark Hirsch MD Kevin McVary MD Ira Sharlip MD Peter Ganz MD |
11:50 AM - 1:05 PM | LUNCH BREAK | |
Section on PDE5- inhibitors: Potential benefits to the CV System; potential safety concerns when dietary supplements are adulterated with PDE-5 inhibitors; and mechanisms | Moderator: Arthur L. Burnett MD |
|
1:05 PM - 1:20 PM | “Potential cardiovascular benefits in general population of men with ED, in diabetics, in men with other risk factors. Are PDE-5 inhibitors cardioprotective?” | Robert A. Kloner MD, PhD |
1:20 PM - 1:35 PM | “Mechanisms of action of PDE-5 inhibitors- summary of findings from basic science research on vascular and cellular mechanisms in ED. Potential impact of PDE-5 inhibition on these systems.” | Arthur L. Burnett MD |
Section on Therapies for ED Beyond PDE-5 Inhibitors | Moderator: Martin Miner MD |
|
1:35 PM - 1:50 PM | “Restorative Therapy for ED: Stem cells, Shock Waves, and Platelet Rich Plasma” | Tom Lue MD |
1:50 PM - 2:05 PM | “Alternatives to PDE5- Inhibitors: Injection therapy and prostheses” | John Mulhall MD |
2:05 PM - 2:40 PM | PANEL 3 | Moderators: Arthur L. Burnett MD Martin Miner MD Robert A. Kloner MD, PhD Arthur L. Burnett MD Tom Lue MD John Mulhall MD |
2:40 PM - 3:00 PM | AFTERNOON COFFEE BREAK | |
Section on Female Sexual Dysfunction | Moderator: Sharon J. Parish MD |
|
3:00 PM - 3:15 PM | “Cardiovascular safety and benefits of PDE-5 inhibition in women with female sexual dysfunction (FSD). (Summary of findings from clinical trials of PDE-5 inhibition in women). ” | Irwin Goldstein MD |
3:15 PM - 3:30 PM | “Neurovascular mechanisms in female sexual arousal disorders and potential targets in women. (Is there a role for topical or oral PDE-5 inhibition in treating female sexual dysfunction (FSD)? ” | Noel Kim PhD |
3:30 PM - 3:45 PM | “Status of diagnostic and treatment guidelines for FSD in women.” | Sharon J. Parish MD |
3:45 PM - 4:15 PM | PANEL 4 | Moderators: Sharon J. Parish MD Ira Sharlip MD Irwin Goldstein MD Noel Kim PhD Sharon J. Parish MD |
4:15 PM - 4:30 PM | Closing Remarks and Summary | Robert A. Kloner MD PhD Raymond Rosen PhD |
Chris is Deloitte Private’s Technology Leader and has responsibility for Consulting’s Mid-Market and Private Company technology strategy, operating approach and solution alignment for mid-market, high growth and privately held companies. He’s involved with Deloitte’s Cloud efforts across the Life Sciences and Healthcare sector in addition to Consulting’s Cloud ERP efforts within the Deloitte Private marketplace.
Chris has broad international business experience and is also skilled in IT Risk. A frequently requested speaker on global competitiveness, technology strategy, and emerging technologies. Chris was recently named to Ad Weeks 2018 Top 50 Indispensable Media, Marketing and Tech Players.
George is a leader in Deloitte’s pharmacy and PBM practice. He has worked in the healthcare industry for over 20 years serving health plans, PBMs, retail and specialty pharmacies, pharmaceutical manufacturers, and integrated delivery networks. Georges focus has been growth strategies, clinical programs, consumer engagement strategies, operating model changes, and M&A work. George led Deloitte’s efforts to help our clients address the opioid crisis, and he has been a frequent speaker on health related topics at a number of conferences including sPCMA, PBMI, and AHIP in 2018.
Prior to Deloitte, George worked at Express Scripts, inVentiv Health, and several start-ups including Silverlink Communications.